CAMBRIDGE, Mass., April 4, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that clinical data from a Phase 1 study of M118, the Company's rationally engineered anticoagulant, will be presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting in Orlando, FL, today at 7:00 a.m. by Ian Fier, Vice President of Development Operations at Momenta and Project Leader of the M118 development program. The poster, entitled: "Pharmacokinetic and Pharmacodynamic Properties of M118, a Novel, Rationally Engineered Low Molecular Weight Heparin, Following IV Injection in Human Volunteers," will be presented during Poster Session II (PII-59).
